scispace - formally typeset
D

Daniel Q. Bach

Researcher at University of California, Los Angeles

Publications -  28
Citations -  457

Daniel Q. Bach is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Surveillance, Epidemiology, and End Results & Medicine. The author has an hindex of 9, co-authored 25 publications receiving 294 citations. Previous affiliations of Daniel Q. Bach include Brigham and Women's Hospital & Beth Israel Deaconess Medical Center.

Papers
More filters
Journal ArticleDOI

Accuracy of self-report in assessing Fitzpatrick skin phototypes I through VI.

TL;DR: Dermatologist-determined FST is more accurate than self-report for FST III through VI and Rephrasing the questions using specific descriptors that have meaning to people with skin of color may allow physicians to more accurately assign a skin phototype and, by inference, assess the risk of these participants developing skin cancer.
Journal ArticleDOI

Primary cutaneous mucinous carcinoma: a systematic review and meta-analysis of outcomes after surgery

TL;DR: Patient demographic characteristics and tumor-specific features may provide predictive information regarding the risk of postsurgical recurrence and metastasis after treatment of PCMC.
Journal ArticleDOI

Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review.

TL;DR: Additional studies will be necessary to further characterize SJS/TEN‐like eruptions on checkpoint inhibitors and determine the optimal management of these cases, which generally improved well on systemic treatment/supportive care and no cases of death were identified.
Journal ArticleDOI

Ganglioside GM3 Depletion Reverses Impaired Wound Healing in Diabetic Mice by Activating IGF-1 and Insulin Receptors

TL;DR: Cutaneous GM3 accumulation may participate in the impaired wound healing of diet-induced diabetes by suppressing keratinocyte insulin/IGF-1 axis signaling.
Journal ArticleDOI

Successful Use of Cyclosporin A for Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Three Children

TL;DR: Some case reports and small studies report the successful use of cyclosporin A (CsA) for SJS/TEN in halting disease progression, fostering reepithelialization, and reducing mortality.